In summary, CD24 has been confirmed to be overexpressed in a variety of cancers, including head and neck cancer [62], breast cancer [63,64], lung cancer [65], colorectal cancer [66], pancreatic cancer [67], hepatocellular carcinoma [68], ovarian cancer [69], urothelial carcinoma [70], prostate cancer [71] and hematological malignancies [72,73]. Here, CD24 is linked to hematologic disorder.